Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: Second line sunitinib treatment following IFN-alpha

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 2101-2105

  Dirican, Ahmet ^a   Kucukzeybek, Yuksel ^a   Erten, Cigdem ^a   Somali, Isil ^a   Demir, Lutfiye ^a   Can, Alper ^a   Payzin, Kadriye Bahriye ^a   Bayoglu, Ibrahim Vedat ^a   Akyol, Murat ^a   Yildiz, Yasar ^a   Köseoglu, Mehmet ^a   Alacacioglu, Ahmet ^a   Tarhan, Mustafa Oktay ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Hmatologic parameters; Metastatic renal cell carcinoma; Sunitinib

Indexed keywords

EID: 84880446963     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.2101     Document Type: Article

References (30)

1. AJCC Cancer Staging Manual, Seventh Edition (2010) publishedby Springer New York, Inc.
2. Aliustaoglu M, Bilici A, Ustaalioglu B, et al (2010). The effect of peripheral blood values on prognosis of patientswith locally advanced gastric cancer before treatment. Med Oncol, 27, 1060-65.
3. Barry RE, Krek W (2004). The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med, 10, 466-72.
4. Demirin H, Ozhan H, Ucgun T, et al (2011). Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res, 128, 358-60.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.
6. Gleave ME, Elhilali M, Fradet Y, et al (1998). Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med, 338, 1265-71.
7. Heng D, Wanling X, Meredith M et al (2009). Prognostic factors for overall survival inpatients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol, 27, 5794-9.
8. J Gastrointest Surg, 12, 1422-8.
9. Keizman D, Ish-Shalom M, Huang P et al (2011). The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer, 48, 202-8.
10. Kim WY, Kaelin WG (2004). Role of VHL gene mutation in human cancer. J Clin Oncol, 22, 4991.
11. Latif F, Tory K, Gnarra J, et al (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260, 1317-20.
12. Maxwell PH, Pugh CW, Ratcliffe PJ, (2011). Activation of the HIF pathway in cancer. Curr Opin Genet Dev, 11, 293-9.
13. Mekhail T, Abou-Jawde R, Boumerhi G, et al (2005). Validation and extension of theMemorial Sloan-Kettering prognostic factors model for survival in patients withpreviously untreated metastatic renal cell carcinoma. J Clin Oncol, 23, 832-41.
14. Motzer R, Bukowski R, Figlin R, et al (2008). Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer, 113, 1552-8.
15. Motzer RJ, Bacik J, Mazumdar M, (2004). Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res, 10, 6302-3.
16. Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24.
17. Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 3584-90.
18. Motzer RJ, Mazumdar M, Bacik J, et al (1999), Amsterdam A, Ferrara JSurvival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530-40.
19. Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24.
20. Ohno Y, Nakashima J, Ohori M, et al (2010). Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol, 184, 873-8.
21. Patard JJ, Leray E, Rioux-Leclercq, N et al (2009). Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol, 23, 2763-71.
22. Patil S, Figlin R, Hutson T, et al (2011). Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol, 22, 295-300.
23. Rodriguez GC, Clarke-Pearson DL, Soper JT et al (1994). The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecl, 83, 445-8.
24. Sahi C, Knox J, Clemons M, et al (2010). Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol, 2, 75-83.
25. Shimada H, Oohira G, Okazumi S, et al (2004). Thrombocytosis associated with poor prognosis inpatients with esophageal carcinoma. J Am Coll Surg, 198, 737-41.
26. Smith RA, Ghaneh P, Sutton R, Raraty M, et al (2008). Prognosis of resected ampullary adenocarcinoma bypreoperative serum CA19-9 levels and platelet-lymphocyte ratio.
27. Sufan RI, Jewett MA, Ohh M, et al (2004). The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol, 287, 1-6.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al (2009). New guidelines to evaluate the response to treatment in solid tumors. European Organization for. Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.
29. Vogelzang NJ, Priest ER, Borden (1992). Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol, 148, 1247-8.
30. Yamanaka T, Matsumoto S, Teramukai S, et al (2004). The baseline ratio of neutrophils to lymphocytes with patient prognosis in advanced gastric cancer. Oncology, 73, 21.